Cargando…

Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence

Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukkari, Mohamad Hekmat, Al-Bast, Basma, Al Tamimi, Raad, Giesing, William, Siddique, Momin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/
https://www.ncbi.nlm.nih.gov/pubmed/37736358
http://dx.doi.org/10.1016/j.ajpc.2023.100579
_version_ 1785107783589298176
author Sukkari, Mohamad Hekmat
Al-Bast, Basma
Al Tamimi, Raad
Giesing, William
Siddique, Momin
author_facet Sukkari, Mohamad Hekmat
Al-Bast, Basma
Al Tamimi, Raad
Giesing, William
Siddique, Momin
author_sort Sukkari, Mohamad Hekmat
collection PubMed
description Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population.
format Online
Article
Text
id pubmed-10509658
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105096582023-09-21 Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence Sukkari, Mohamad Hekmat Al-Bast, Basma Al Tamimi, Raad Giesing, William Siddique, Momin Am J Prev Cardiol Short Report Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of ASCVD. Those with elevated lipoprotein (a) [Lp(a)] levels are at increased risk of ASCVD. In this article, we provide an overview of studies that have explored the use of aspirin therapy in individuals with elevated Lp(a). We discuss the potential mechanisms by which aspirin therapy may reduce ASCVD risk, and present a review of the data on the effectiveness of aspirin therapy in reducing ASCVD risk in individuals with elevated Lp(a). The presented evidence suggests that individuals with elevated Lp(a) benefit more from aspirin therapy for reduction of ASCVD events than the general population. Elsevier 2023-09-01 /pmc/articles/PMC10509658/ /pubmed/37736358 http://dx.doi.org/10.1016/j.ajpc.2023.100579 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Report
Sukkari, Mohamad Hekmat
Al-Bast, Basma
Al Tamimi, Raad
Giesing, William
Siddique, Momin
Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title_full Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title_fullStr Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title_full_unstemmed Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title_short Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
title_sort is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated lipoprotein (a)—a review of the evidence
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/
https://www.ncbi.nlm.nih.gov/pubmed/37736358
http://dx.doi.org/10.1016/j.ajpc.2023.100579
work_keys_str_mv AT sukkarimohamadhekmat isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence
AT albastbasma isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence
AT altamimiraad isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence
AT giesingwilliam isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence
AT siddiquemomin isthereabenefitofaspirintherapyforprimarypreventiontoreducetheriskofatheroscleroticcardiovasculardiseaseinpatientswithelevatedlipoproteinaareviewoftheevidence